Skip to main content

Table 1 Baseline characteristics of included study participants from the ESTHER (= 5258) and UK Biobank study (= 305,394)

From: Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies

Characteristics

ESTHER

(= 5258)

UK Biobank

(= 305,394)

 

n (%)a

n (%)a

Age [years]

 55–59

1020 (19.4)

90,134 (29.5)

 60–64

1504 (28.6)

120,315 (39.4)

 65–69

1577 (30.0)

92,559 (30.3)

 70–79

1157 (22.0)

2386 (0.8)

Sex

 Female

2852 (54.2)

163,705 (53.6)

 Male

2406 (45.8)

141,689 (46.4)

Low-dose ASA use

962 (18.3)

57,068 (18.7)

Number of individuals in household

 1

854 (16.2)

63,706 (20.9)

 2

3244 (61.7)

182,426 (59.7)

 >2

1160 (22.1)

59,262 (19.4)

School education [years]

 ≤9

3915 (74.5)

91,181 (29.9)

 10–11

732 (13.9)

79,493 (26.0)

 ≥12

611 (11.6)

134,720 (44.1)

BMI [kg/m2]

 <25

1409 (26.8)

93,414 (30.6)

 25–<30

2543 (48.4)

134,764 (44.1)

 ≥30

1306 (24.8)

77,216 (25.3)

Smoking

 Never

2757 (52.4)

157,241 (51.5)

 Former

1785 (34.0)

120,990 (39.6)

 Current

716 (13.6)

27,163 (8.9)

Alcohol consumption b

 None

1615 (30.7)

94,298 (30.9)

 Low or moderate

3562 (67.7)

174,310 (57.1)

 High

81 (1.5)

36,786 (12.1)

Physical activity c

 Inactive

991 (18.9)

44,280 (18.4)

 Low

2439 (46.4)

100,178 (41.7)

 Medium or high

1828 (34.8)

95,877 (39.9)

Coronary heart disease

 No

4290 (81.6)

285,316 (93.4)

 Yes

968 (18.4)

20,078 (6.6)

Hypertension

 No

2235 (42.5)

202,175 (66.2)

 Yes

3023 (57.5)

103,219 (33.8)

Diabetes

 No

4478 (85.2)

286,337 (93.8)

 Yes

780 (14.8)

19,057 (6.2)

Depression

 No

4495 (85.5)

273,742 (89.6)

 Yes

763 (14.5)

31,652 (10.4)

Total cholesterol [mg/dL]

 <200

1662 (31.6)

97,264 (31.9)

 200–<240

1786 (34.0)

102,938 (33.7)

 ≥240

1810 (34.4)

105,192 (34.4)

HDL [mg/dL]

 <40

968 (18.4)

36,560 (12.0)

 40–<60

2614 (49.7)

156,740 (51.3)

 ≥60

1676 (31.9)

112,094 (36.7)

CRP [mg/L]

 <1

1339 (25.5)

107,846 (35.3)

 1–<3

2053 (39.1)

117,782 (38.6)

 ≥3

1866 (35.5)

79,766 (26.1)

APOE genotypes

 ε4 non-carrier

3881 (73.8)

219,088 (71.7)

 ε2/ε4 or ε3/ε4

1295 (24.6)

79,134 (25.9)

 ε4/ε4

82 (1.6)

7172 (2.4)

  1. Abbreviations: ASA acetylsalicylic acid, BMI body mass index, CRP C-reactive protein, HDL high-density lipoprotein
  2. aNumbers of imputed complete dataset number 1. The proportion of imputed missing values of each variable is shown in Suppl. Table A2
  3. bDefinition of low or moderate alcohol consumption: women 0 to 39.99 gram ethanol/day (g/d) or men 0 to 59.99 g/d; definition of high alcohol consumption: women ≥40 to 39.99 g/d or men ≥60 g/d
  4. cIn ESTHER: “Inactive” was defined by <1 h of vigorous and <1 h light physical activity per week. “Medium or high” was defined by ≥2 h of vigorous and ≥2 h of light physical activity/week. All other amounts of physical activity were grouped into the category “Low”. In UK Biobank: “Inactive” was defined by ≤1 h of performing walking, moderate and vigorous activity. “Medium or high” was defined by >2 h of performing walking, moderate and vigorous activity. All other amounts of physical activity were grouped into the category “Low”